Terns Pharmaceuticals, Inc. Shareholders' Equity
Terns Pharmaceuticals, Inc. had Shareholders' Equity of $1.01 billion as of 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-03-30
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.01B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $284.07M.
- 2025-06-30: Stockholders' Equity Attributable to Parent $305.23M.
- 2025-03-31: Stockholders' Equity Attributable to Parent $326.04M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2025-12-31 | $1.01B 10-K · filed 2026-03-30 |
| 2025-09-30 | $284.07M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $305.23M 10-Q · filed 2025-11-10 |
| 2025-03-31 | $326.04M 10-Q · filed 2025-11-10 |
| 2024-12-31 | $345.87M 10-K · filed 2026-03-30 |
| 2024-09-30 | $364.47M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $218.68M 10-Q · filed 2025-11-10 |
| 2024-03-31 | $236.72M 10-Q · filed 2025-11-10 |
| 2023-12-31 | $255.37M 10-K · filed 2026-03-30 |
| 2023-09-30 | $258.43M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $274.15M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $287.68M 10-Q · filed 2024-11-12 |
| 2022-12-31 | $276.94M 10-K · filed 2025-03-20 |
| 2022-09-30 | $183.69M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $137.22M 10-Q · filed 2023-11-14 |
| 2022-03-31 | $148.72M 10-Q · filed 2023-11-14 |
| 2021-12-31 | $160.30M 10-K · filed 2024-03-14 |
| 2021-09-30 | $172.16M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $181.33M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $190.00M 10-Q · filed 2022-11-09 |
| 2020-12-31 | -$117.44M 10-K · filed 2023-03-27 |
| 2020-09-30 | -$119.81M 10-Q · filed 2021-11-15 |
| 2020-06-30 | -$109.28M 10-Q · filed 2021-11-15 |
| 2020-03-31 | -$99.73M 10-Q · filed 2021-11-15 |
| 2019-12-31 | -$90.76M 10-K · filed 2022-03-07 |